Liječenje raka zauzima globalno selo: Cancer Moonshot Pathways

Napomena: Predsjednik Joe Biden je u februaru pokrenuo inicijativu “Cancer Moonshot” koja ima za cilj smanjenje stope smrtnosti od raka za 50% u narednih 25 godina. Ovo je dio niza postova sa stručnjacima za rak koji nude prijedloge koji će pomoći Moonshotu da uspije. Povezane, predstojeće 3^rd Forbes China Healthcare Summit” 27. avgusta (26. avgusta ET) će se pozabaviti “Novim međunarodnim smjernicama za ponovno zapaljeni Moonshot” kao svojom glavnom temom ove godine. Registracija je besplatna. Za više informacija kontaktirajte: [email zaštićen]

BeiGene CEO and co-founder John V. Oyler made a mark in the international fight against cancer by leading the first company to have a drug developed in China obtain FDA approval — the anti-cancer drug, Brukinsa, in 2019. BeiGene is global company with administrative offices Basel, Beijing and Cambridge.

The Pennsylvania-born entrepreneur’s success – he has a fortune worth more than $1 billion on the Forbes Real-Time Billionaires list – has given him insights into the role of accessibility of clinical trials for promising new cancer drugs to large populations both in the U.S. and globally.

“Enrolling in a clinical trial is out of reach for many patients,” Oyler noted in written comments about the Cancer Moonshot. “Trials are often run predominantly at major clinical centers, and an unintended outcome is that the participants are limited in terms of types of cancer, race or ethnicity, geography and socio-economic background. Many more hospitals and community oncology practices treating patients with cancer should be supported and equipped to participate in clinical trials, he said. This would reduce barriers to participating in clinical trials and allow all patients to receive the innovative investigational medicines, while also improving the diversity in patient populations and the robustness of data,” he said.

“This means that the industry must forge relationships with community hospitals and physicians, to help them build expertise and capabilities to participate in clinical trials and contribute high-quality data,” Oyler suggested. For its part, BeiGene last year launched a Clinical Trial Diversity Initiative to support training for clinicians and staff in underserved communities, patient education, and advocacy efforts.

In addition, Oyler said, “Accelerating science and innovative therapies for all requires continuing to advance multi-regional clinical trials that enable the industry to expedite enrollment by providing a broader population of potential trial participants and enabling more diverse racial and ethnic representation.”

“As the industry expands the quality of clinical trial participant recruitment in the U.S., it’s important to highlight that investments in the U.S. alone will not be enough to fight cancer. In developed economies like the U.S., there is a growing shortage of people eligible for clinical trials, as many have access to medicines outside a clinical trial setting, there are fewer ‘treatment naïve’ patients, and clinical trials are often limited to major medical centers,” Oyler said.

BeiGene, for instance, has trial sites in 45 countries and, to date, has received approval from regulatory authorities covering 50 countries and regions for Brukinsa.

Further, he said, the industry — in collaboration with health authorities and regulators — must continue to explore how to better prioritize patient-reported outcomes and developing tools to quantify patient experience and quality of life measures. “One example of this is the ongoing conversations with stakeholders led by the FDA in its Patient Focused Drug Development initiative,” Oyler said.

Finally, while the ambitious aims of the Cancer Moonshot are both “noble and vital,” it is equally important to consider how to expand access to existing medicines – an effort he calls. “Project Groundshot.”

“This is why we recently joined the Access to Oncology Medicines Coalition, an initiative led by the Union for International Cancer Control to build supply capacity and expand access to lifesaving cancer therapies in low- and middle-income countries. Initiatives like the coalition underscore the potential for public- private partnerships to bridge a geographic gulf in cancer care,” he concluded.

Pogledajte povezane postove:

Upoznajte naučnika koji koordinira novi Moonshot raka Joea Bidena

„Zašto je rak manje važan za izlečenje brže od Covida?“: Putevi raka Moonshot

Inovativna rješenja za rak zahtijevaju inovativne financije: Cancer Moonshot Pathways

Potaknite borbu protiv raka koji pogađa djecu: Putevi raka Moonshot

Probijte barijere za pokretanje napretka: Putevi raka Moonshot

Social Justice, Outreach, Global Collaboration: Cancer Moonshot Pathways

Biden zaslužuje priznanje za borbu protiv raka: Cancer Moonshot Pathways

Ubrzajte izlječenje kroz međunarodnu saradnju u kliničkim ispitivanjima: putevi raka Moonshot

Zatvorite jaz između istraživanja otkrića i brige o pacijentima: putevi raka Moonshot

@rflannerychina